Immunity and vaccine development in Pasteurella multocida infections.
The role of LPS in immunity was studied using monoclonal antibodies (MAbs) and active immunisation experiments. A panel of six MAbs produced against Pasteurella multocida serotype B:2 reacted with the LPS of serotypes B:2 and B:5, but not with other serotypes. The MAbs could opsonise P. multocida for phagocytosis by mouse macrophages, but were not bactericidal in the presence of complement. They conferred only partial passive protection in mice. Similar results showing only partial protection were obtained when purified LPS was used to actively immunise mice prior to challenge, suggesting that LPS plays a partial role in immunity to infection. The aroA gene from P. multocida serotypes A:1 and A:3 was cloned and inactivated by insertion of a kanamycin resistance gene. The mutated gene was re-introduced onto the chromosome by allelic exchange. The resultant aroA mutants were highly attenuated in a mouse model system, with a 6-log decrease in ID50. Virulence could be restored by complementation with a functional aroA gene. Mice immunised with two doses of the live mutants were protected against lethal challenge with the homologous parental strain, but not against the heterologous strain. P. multocida A:1 and A:3 expressed unique proteins when grown in iron-restricted medium. Moreover, the outer membrane (OM) fractions of these cells contained novel proteins of 75 kDa, 85 kDa and 94 kDa molecular mass. Mice were immunised with OM fractions prepared from serotype A:3 grown in iron-restricted (OM Fe-) or iron-replete (OM Fe+) media. When low challenge doses were used, both immunogens protected mice against serotype A:3, but only the OM Fe- fraction protected mice against heterologous challenge with serotype A:1. When higher challenge doses were used, only partial protection was observed.
Adler
B
B
Department of Microbiology, Monash University, Clayton, Victoria, Australia.
Chancellor
R
R
Homchampa
P
P
Hunt
M
M
Ruffolo
C
C
Strugnell
R
R
Wapling
D
D
D051229:3-Phosphoshikimate 1-Carboxyvinyltransferase; D019883:Alkyl and Aryl Transferases; D000818:Animals; D000911:Antibodies, Monoclonal; D001428:Bacterial Vaccines; D003001:Cloning, Molecular; D005798:Genes, Bacterial; D005816:Genetic Complementation Test; D007114:Immunization / Q000379:methods*; D007116:Immunization, Passive; D008070:Lipopolysaccharides / Q000276:immunology*; D008264:Macrophages / Q000276:immunology; D051379:Mice; D010326:Pasteurella Infections / Q000276:immunology* / Q000517:prevention & control; D016979:Pasteurella multocida / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D010587:Phagocytosis; D014166:Transferases / Q000096:biosynthesis / Q000276:immunology*; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014774:Virulence
D000911:Antibodies, Monoclonal; D001428:Bacterial Vaccines; D008070:Lipopolysaccharides; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014166:Transferases; D019883:Alkyl and Aryl Transferases; D051229:3-Phosphoshikimate 1-Carboxyvinyltransferase